Blood-based diagnosis of neurodegeneration could become more accessible and affordable through synthetic alternatives to costly antibody-based tests. Neurofilament light chain levels in blood correlate strongly with brain damage progression in Alzheimer's disease, making it a prime target for diagnostic development.
Researchers engineered two DNA aptamers—MN711 and MN734—that bind neurofilament light chain with dissociation constants of 11 nM and 8.1 nM respectively. These synthetic molecules demonstrated binding affinity comparable to current anti-NfL antibodies while maintaining selectivity against other Alzheimer's proteins including amyloid beta variants and phosphorylated tau181. The aptamers adopt parallel G-quadruplex structures and function effectively in human plasma samples.
This advancement addresses critical limitations in current neurodegeneration diagnostics. Antibody-based assays require expensive reagents, cold-chain storage, and sophisticated laboratory infrastructure, limiting accessibility in resource-constrained settings. DNA aptamers offer superior stability, lower production costs, and simplified storage requirements while maintaining diagnostic precision. The selective binding demonstrated here suggests these molecules could enable point-of-care testing devices for early Alzheimer's detection.
However, clinical validation remains essential. The study tested aptamer performance only in spiked plasma samples rather than patient blood containing naturally occurring neurofilament levels. Additionally, the correlation between aptamer-detected NfL and actual disease progression requires longitudinal studies. While promising for biosensor development, these findings represent an early technical milestone rather than an immediate diagnostic breakthrough. The work nonetheless establishes a foundation for developing more accessible neurodegeneration screening tools.